Inequitable Conduct After Therasense: Definitely Harder to Prove

Specific intent to deceive the USPTO did not exist where an inventor removed mention of a reference from his patent application, and then testified that the "reference was cumulative or merely provided background information."  Imura International U.S.A., Inc. v. HR Technology, Inc., No. 08-2220 (D. Kans. April 24, 2012).  The party asserting inequitable conduct also failed to show materiality under the but-for standard of Therasense.  This case is worth noting as yet another example of how Therasense has had a tangible, limiting impact on assertions of inequitable conduct.  Asserting inequitable conduct is unquestionably a harder defense to succeed upon than it used to be.

Upcoming Webinar

PTAB Practice: Recent Developments in Estoppel
November 21, 2019 at 12:00 pm EST
There are a wide range of estoppel issues that may be triggered under the America Invents Act (AIA) as a result of proceedings before the Patent Trial and Appeal Board (PTAB).  These estoppel issues complicate decision making in pursuing parallel pr…Register

Subscribe